MYCOPHENOLATE MOFETIL AND PREDNISONE AS MAINTENANCE TREATMENT AFTER KIDNEY TRANSPLANTATION
- 1 May 1997
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 63 (10) , 1530,1531-1
- https://doi.org/10.1097/00007890-199705270-00029
Abstract
Hemolytic uremic syndrome (HUS) is an infrequent but severe complication of kidney transplantation. Cyclosporine-induced microangiopathy may be the causative factor in allograft recipients with HUS. In transplant recipients with HUS, discontinuation of cyclosporine is generally advised. This often leads to loss of the graft. An adult kidney transplant recipient developed HUS in the third week after transplantation. Maintenance immunosuppression was changed to mycophenolate mofetil and prednisone after cyclosporine was discontinued. The change in immunosuppressive therapy led to remission of the HUS and stable graft function. In transplant recipients receiving cyclosporine who suffer from HUS, the possibility of conversion from cyclosporine to mycophenolate mofetil should be considered. As this case shows, complete remission of HUS and maintenance of the graft are possible.Keywords
This publication has 6 references indexed in Scilit:
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- MYCOPHENOLATE MOFETIL FOR THE TREATMENT OF REFRACTORY, ACUTE, CELLULAR RENAL TRANSPLANT REJECTION1Transplantation, 1996
- Mycophenolate MofetilDrugs, 1996
- Hemolytic uremic syndrome in solid-organ transplant recipientsTransplant International, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995